skip to Main Content
Phil Landrigan

Archived Blog Posts
  • Eaters Deserve More Complete Information About Nutrition and Health Impacts on Food Labels  

    Multiple lines of evidence point to consumer food choices as major contributors to diet-related disease, and poor health and fitness. In a peer-reviewed journal article published today, authors Chuck Benbrook and Robin Mesnage cite studies indicating that “Some 90% of the estimated USD 4.3 trillion in annual health care costs in the US is triggered or made worse by poor food quality and diet-related disease.” Benbrook is the founder and former executive director of the Heartland Health Research Alliance (HHRA). The authors recommend novel metrics on both the nutrient density of food, and how to more accurately and usefully characterize the degree of food processing and its impacts on public health. The article is open access in the journal Foods and entitled “Enhanced Labeling to Promote Consumption of Nutrient Dense Foods and Healthier Diets.” The core nutrient density metric is a ratio: the percent of daily nutrient needs satisfied by a serving of food relative to the percent of a 2000 calorie daily diet taken up by the serving of food. This single metric is unmatched in comprehensively reflecting the nutritional quality of food. A graphic option to convey the metric on packaging is presented in Figure 3 in the new paper: A novel graphic is presented in Figure 5 to which integrates both the nutrient density and food processing metrics and graphics in a single graphic, shown below. The impacts of ultra-processed food (UPF) on public health outcomes is among the hottest topics in nutrition, medical, and public health journals, and media coverage on food quality and health outcomes. At the request of the journal, the authors developed a video abstract that explains the paper’s goals, methods, and key findings and recommendations. The authors conclude their paper with these observations: Transparent and accurate food product-specific ingredient and nutrient composition data should determine the content of nutrition health labeling. Efforts to soften the message should be resisted in light of the overwhelming need for new food labels that help bring about substantial improvements in food nutritional quality and dietary choices. Benbrook and Mesnage’s paper builds on public comments HHRA submitted in response to the US Food and Drug Administration (FDA) proposed rule in 2023 to update the definition of the term “healthy” on food labels. The proposed role would require foods labeled “healthy” to contain minimum amounts of foods recommended by USDA’s Dietary Guidelines, and to limit saturated fat, sodium, added sugar and other less healthy nutrients. Entitled “Food Labeling: Nutrient Content Claims; Definition of Term `Healthy’”, the comments recommended new  nutrition/health messaging on the front of food packaging. Co-authors of comments included the chair of HHRA’s Policy Advisory committee Dr. Kathleen Merrigan, HHRA science advisors, and other experts working on how changes in farming systems and technology can increase the nutritional quality of food: Dr. Hannah Flower, Dr. Donald R. Davis, Dr. David Montgomery and Anne Biklé. In the comments, the authors introduced “NuCal” as a name for their new system. Resources HHRA February 2023 comments to the FDA. Benbrook and Mesnage (2024). Enhanced Labeling to Promote Consumption of Nutrient Dense Foods and Healthier Diets, Foods. https://doi.org/10.3390/foods13213377 Video Abstract: “Enhanced Labeling to Promote Consumption of Nutrient Dense Foods and Healthier Diets”

  • HHRA Weighs in on Key Pesticide Issues Under Review by the National Organic Standards Board

    HHRA and ORG-Tracker, represented by Dr. Chuck Benbrook and Dr. Brian Baker, submitted comments to the Agricultural Marketing Service at the USDA in advance of the National Organic Standards Board (NOSB) meeting in Portland, Oregon, from October 22nd to 24th, 2024. Drs. Benbrook and Baker will both attend the conference and deliver public comments. ORG-Tracker is a project carried out by HHRA. It aggregates pesticide residue data from inspections of organic farms carried out by certifiers. The tables generated by ORG-Tracker utilize the results of certifier testing to compare residue frequency and risk levels to food produced on conventional farms. The team is working to more effectively highlight gaps and challenges faced by certification agencies to answer questions like What crops should we be testing, and where? Is a pesticide residue found in an organic sample likely caused by accident, pesticide drift, or an intentional and illegal application? How can we modify organic programs to better mitigate risk? The comments delivered to the USDA discuss risk-based certification, pesticide residue testing, and policies impacting the incorporation of so-called inert ingredients in the biopesticides approved for use on organic farms. They argue for a more rigorous, comprehensive, and health-focused approach to risk oversight. Regarding residue testing, they advocate for more expansive and effective data aggregation to inform consumers and the organics community. Finally, for inert ingredients, they recommend further review of current policy, including increased transparency of ingredients in pesticide products. Thank you to Drs. Benbrook and Baker for your advocacy and hard work!   The three sets of comments are posted on HHRA’s website as part of our policy program: Comments to the NOSB on the Risk-Based Certification Discussion Document Under Consideration During the October 2024 Meeting in Portland, Oregon Written Comments on the NOSB Discussion Document “Residue Testing for the Global Supply Chain” Comments on the Inert Ingredients in Organic Pesticide Products Proposal dated August 13, 2024   Drs. Benbrook and Baker also submitted and presented comments at the Spring 2024 meeting of the NOSB, which are available on HHRA’s Policy and Regulatory Reform page.

  • Dr. Kimberly Yolton joins HHRA board

    Dr. Yolton is a developmental psychologist and epidemiologist serving as Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center. Her interests include exposures and experiences that may alter a child’s developmental trajectory from infancy through adolescence. She collaborates on research projects on typical child development as well as those focused on the impact of exposures to environmental toxicants, opiates and stress during early development.

  • Paul Hartnett, HHRA’s Executive Director

      Paul Hartnett has served as HHRA’s CFO since our founding . With the departure of Russell King, Paul has now joined the board and Executive Director. We thank Russell for his service and wish him the best in his future endeavors.

  • Heartland Study Enrolls 1,000th Mother-Infant Pair

    July 19, 2024 – In June of this year, the Heartland Study achieved a major milestone, enrolling its 1,000th mother-infant pair. Enrollment is now at 50% of goal. The objective of the Study is to help fill major gaps in our understanding of the impacts of herbicides on maternal and infant health. Currently in Phase 1, the Study is focused on evaluating associations between herbicide concentrations in body fluids and tissue samples from pregnant women and infants, and pregnancy/childbirth outcomes. Phase 2 is designed to evaluate potential associations between herbicide biomarkers and early childhood neurological development. Much appreciation for the mothers enrolled, and the entire Heartland Study Team including scientists, support staff and clinicians for this tremendous achievement, and for our funders to making this work possible. Read more about the study including peer-reviewed studies published in Chemosphere and Agrichemicals at our publications  page. The investment required to conduct this study exceeds $1 million each year. You can support this important work by making a donation here.

New Study in Rats Establishes Strong Link Between Roundup Exposure and Early Onset Leukemia

Nov 6th, 2023
Nov 6th, 2023
Phil Landrigan

By Philip Landrigan, MD, Chair, HHRA Science Advisory Committee

The Ramazzini Institute (RI) is concluding its five-year Global Glyphosate Study (GGS), the most detailed independent study ever conducted on the toxicity of glyphosate and glyphosate-based herbicides (GBHs). The study integrates three parts: a two-year cancer bioassay in rats; a two-generation rat reproduction study, and a full battery of in vitro and in vivo genotoxicity assays.

The study examines three forms of glyphosate: pure glyphosate; Roundup BioFlow, a GBH form used in the EU; and Roundup RangerPro, a GBH heavily used in the USA.  Each form was administered to the rats via drinking water at three dose levels – 0.5, 5.0 and 50 mg/kg/day. These exposure levels are generally considered safe by regulators. Exposures began in prenatal life. There was also a control group not exposed to any glyphosate.

A full set of FAQs describes design features and study goals, and the results of GGS pilot studies (need for independent research, study design and endpoints, and impacts on the microbiome).

Three unique features of the Ramazzini Institute’s Global Glyphosate Study distinguish it from all previous studies:

  • It studies real-life exposures:No previously published long-term carcinogenicity or multi-generational lab studies have examined glyphosate’s toxicity at real-life exposure levels generally considered safe.
  • It is comprehensive and independent:Hundreds of studies have been carried out on glyphosate by both the pesticide industry and independent scientists using high doses over long-term periods. None, however, have been both comprehensive (covering long-term toxicity, carcinogenicity and multi-generational effects) and independent of the pesticide manufacturing industry.
  • It examines whether Glyphosate is an endocrine disruptor:The GGS previously published a pilot study showing endocrine and reproductive toxicity in rats at glyphosate doses currently considered safe by US regulatory agencies. These findings were later confirmed in a human population of mothers and newborns exposed to glyphosate during pregnancy.

Instead of testing maximum tolerated dose levels, as in the case of glyphosate cancer bioassays conducted by GBH registrants, the GGS is assessing the health effects of doses that are much closer to real-world exposure levels. The GGS dose levels include the EU Acceptable Daily Intake level of 0.5 mg/kg/day, 5 mg/kg/day (10-X the EU ADI), and the EU No Observable Adverse Effect Level (NOAEL) of 50 mg/kg/day. These doses are 100-fold to 1,000-fold lower than the doses in registrant-commissioned toxicology studies.

First Key Findings Released
On Oct. 25, 2023, the RI released the first major findings from the GGS rat cancer bioassay. The press release states:  “A multi-institutional international toxicological study has found that low doses of glyphosate-based herbicides cause leukemia in rats. Importantly, half of the leukemia deaths identified in the study groups occurred at an early age.”

No rats in the unexposed control group died of leukemia. Four leukemia deaths were recorded in the rats exposed to pure glyphosate. Three leukemia deaths occurred in the rats exposed to Roundup BioFlow. Seven leukemia deaths occurred in the rats exposed to Ranger Pro. In the formulated GBH treatment groups, the higher the glyphosate dose, the greater the number of leukemia deaths.

In its presentation of results, the RI team stressed that:  “An additional very important finding is that about half of the leukemias deaths seen in the glyphosate and glyphosate-based herbicides groups occurred at less  than one year of age. In previous studies, no case of leukemia was observed in the first year of age in more than 1600 historical controls in carcinogenicity studies conducted by either the Ramazzini Institute or the US National Toxicology Program (NTP).”

The RI team still has substantial work ahead to finish analyzing all of the tissues collected in the three legs of the GGS. They must conduct careful statistical analyses to ferret out statistically significant links between glyphosate or GBH exposures and markers of adverse health effects

One of their most important challenges – and opportunities – is to combine insights from each of the three parts of the GGS into a cohesive, consistent set of findings that identify how exposures to glyphosate and GBHs can impair health, as well as the mechanisms leading to reproductive problems or chronic disease.

The time it will take the RI to complete the core scientific papers reporting the results of the GGS will depend on their success in raising additional funding. Once the first round of papers is  complete in 2024, the RI looks forward to pursuing several additional, collaborative research projects to explore glyphosate/GBH roles in epigenetic change, impairment of the microbiome, and impacts on children’s development and metabolic disease.

The addition of the RangerPro treatment group has provided valuable information that would not otherwise be available and shown that RangerPro and other POEA-based GBH formulations are among those most likely to cause leukemia. The RangerPro exposure groups may help resolve critical questions on whether and how exposures to glyphosate or GBHs might be contributing to reproductive problems, birth defects, and developmental anomalies, as well as cancer and other chronic metabolic diseases.

Given that glyphosate-based herbicides remain by far the most heavily applied pesticides in the US and globally, with well over three-quarters of humankind exposed on a near-daily basis, time is of the essence in seeking clarity on the adverse health outcomes stemming from exposure to this herbicide.

Back To Top